April 15, 2008
PIramed, the first spin-off company from the Ludwig Institute for Cancer Research, was today acquired by the pharmaceutical company, Roche. PIramed was formed in 2003 to exploit inhibitors targeting the PI-3 kinase family of enzymes. The inhibitors - and most of the PI-3 kinases - were first characterized by a group led by the Founding Director of the LICR London Branch, Michael D. Waterfield, F.R.S.